Back to search results

Study of Mobility After Pulmonary Embolism

This study is looking at how a home-based exercise program can improve mobility for people who have had a pulmonary embolism (PE), which is a blood clot in the lungs. The exercise program involves working out 3 days a week for 20 minutes per session, over 12 weeks, with guidance from an exercise physiologist. We are looking for adults aged 18 to 80 who have had an acute intermediate-risk PE, meaning they have a blood clot in their lungs and some signs of strain on their heart's right side. The main goal is to see how much your physical capacity changes from the start of the study to 3 and 6 months later. The current recruitment status is unclear.

Study design
This is an interventional study planning to enroll 100 participants. It is not specified if it is randomized or blinded.
What's involved
You would participate in an exercise training program for 12 weeks. Your physical capacity will be measured at the beginning, at 3 months, and at 6 months.
Compensation
Not stated in the trial record.
Follow-up
Your physical capacity will be measured at 3 months and 6 months after the start of the study.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06695247

A Study of Mobility Outcomes in Post-Pulmonary Embolic Disease

Recruiting
NAAges 18–80InterventionalTreatment
Mayo Clinic
~100 participants
Updated 2026-08-10 on ClinicalTrials.gov
What's tested:Exercise Training

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Change in physical capacity from baseline
Measured over Baseline, 3 Months, 6 Months

Conditions

Pulmonary Embolism

Explore related trials

Pulmonary Embolism

NCT06695247

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Mayo Clinic Rochester

    Rochester, Minnesotastudy coordinator listed

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Stan Henkin, M.D. · PRINCIPAL_INVESTIGATOR · Mayo Clinic

Who to contact

Stan Henkin, M.D.
[email protected]
507-284-8612
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Intraluminal filling defect in segmental or larger vessels on computed tomography pulmonary angiography or high-probability ventilation/perfusion scan AND
Evidence of right ventricular enlargement by computed tomography (RV to LV ratio \>1) or echocardiography; and/or right ventricular dysfunction by transthoracic echocardiography. These imaging characteristics must be in the setting of acute PE rather than explained by a prior chronic condition.
Intraluminal filling defect in segmental or larger vessels on computed tomography pulmonary angiography or high-probability ventilation/perfusion scan AND
Evidence of right ventricular enlargement by computed tomography (RV to LV ratio \>1) or echocardiography; and/or right ventricular dysfunction by transthoracic echocardiography. These imaging characteristics must be in the setting of acute PE rather than explained by a prior chronic condition; AND
Hypotension (systolic blood pressure \< 90 mm Hg sustained for more than 15 minutes; or requiring vasopressors) or cardiogenic shock due to acute pulmonary embolism.

Exclusion

Inability to ambulate independently, which is necessary to perform 6MWD (may be self-reported or as deemed by physical therapy during inpatient evaluation).
If patient requires supplemental oxygen during ambulation, this does not exclude patient from participation and will be noted during eCRF.
Prior history of pulmonary embolism
History of CTEPH or pulmonary arterial hypertension
Unable to read a questionnaire in English
Unable to return for baseline, 3- or 6-month follow-up visit
Pregnancy-associated pulmonary embolism
Life expectancy \<1 year based on comorbidities
Unable/unwilling to provide informed written consent

What this trial measures

  • Change in physical capacity from baselineBaseline, 3 Months, 6 Months

    Physical capacity will be determined by 6-minute walk distance (6MWD)